SCHEMBL24458424

SCHEMBL24458424

C=CC(=O)N1CC(C#Cc2c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc3n2C(C)C)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 20/20 0.52
▸ EGFR P00533 5/20 0.52
▸ TEC P42680 4/20 0.52
▸ BMX P51813 4/20 0.52
▸ BLK P51451 3/20 0.52
▸ TXK P42681 3/20 0.52
▸ ITK Q08881 3/20 0.52
▸ ERBB2 P04626 2/20 0.52
▸ RET P07949 2/20 0.52
▸ FLT3 P36888 2/20 0.52
▸ ERBB4 Q15303 2/20 0.52
▸ PDGFRB P09619 1/20 0.52
▸ LYN P07948 2/20 0.50
▸ FGFR2 P21802 2/20 0.50
▸ RIPK2 O43353 1/20 0.50
▸ NR1I2 O75469 1/20 0.50
▸ SLC22A3 O75751 1/20 0.50
▸ LATS1 O95835 1/20 0.50
▸ NUDT14 O95848 1/20 0.50
▸ ABL1 P00519 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24458542 0.94 BTK (0.56) BTKEGFRTECBMXBLK
SCHEMBL24458294 0.92 BTK (0.57) BTKEGFRTECBMXBLK
SCHEMBL24458464 0.92 BTK (0.57) BTKEGFRTECBMXBLK
SCHEMBL24458355 0.92 BTK (0.54) BTKEGFRTECBMXBLK
SCHEMBL31523842 0.90 BTK (0.58) BTKEGFRTECBMXTXK
SCHEMBL24458744 0.88 BTK (0.50) BTKEGFRTECBMXBLK
SCHEMBL24458599 0.87 BTK (0.55) BTKEGFRTECBMXBLK
SCHEMBL24458396 0.87 BTK (0.57) BTKEGFRTECBMXBLK
SCHEMBL24458630 0.86 BTK (0.51) BTKEGFRTECBMXBLK
SCHEMBL31523948 0.86 BTK (0.51) BTKEGFRTECBMXBLK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154154-A1 SRC INHIBITORS AND USES THEREOF RELAY THERAPEUTICS, INC. 2025-05-15 — — US disclosed
WO-2022109551-A1 SRC INHIBITORS AND USES THEREOF RELAY THERAPEUTICS, INC. (US) 2022-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154154-A1 SRC INHIBITORS AND USES THEREOF SRC, LCK, FYN BTK 7/4885EGFR 51/4885TEC 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback